This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Macular Degeneration  • Alert me on articles by topic  Social Bookmarking   What's this?

AREDS Report No. 14

Age-Related Eye Disease Study Research Group^*

Arch Ophthalmol. 2005;123:1207-1214.

Objective  To describe the ability of the National Eye Institute Visual Function Questionnaire (NEI-VFQ) to detect meaningful change over time (responsiveness) to the primary Age-Related Eye Disease Study outcomes.

Methods  The 25-item NEI-VFQ plus appendix was administered at 2 visits at 1- to 4-year intervals to 4119 participants in the Age-Related Eye Disease Study. Events evaluated were progression to advanced age-related macular degeneration (AMD), visual acuity (VA) loss of at least 15 letters, and lens opacity progression. Responsiveness was measured by the t statistic, effect size (ES), responsiveness statistic, and area under the receiver operating characteristic curve. Variance components were used to estimate the contributions of events to variability of the NEI-VFQ score.

Results  Overall NEI-VFQ score was responsive to AMD progression (t = 14.0; P<.001; ES = 0.81) and VA (t = 16.2; P<.001; ES = 0.74). Mean changes ranged from 11 to 25 points for the subscales of general vision, near and distance activities, social functioning, mental health, role difficulties, dependency, and driving. The NEI-VFQ was unresponsive to lens opacity progression, although when the event occurred in the eye with the best vision at the first administration, the lens opacity ES was moderate for the color vision (ES = 0.62) and driving subscales (ES = 0.66). Progression to advanced AMD and VA loss contributed significantly to the variation in the mean difference in overall VFQ score.

Conclusions  Changes in the NEI-VFQ overall and subscale scores of 10 points or more are associated with clinically significant changes in vision and AMD. This finding may assist the design of interventional studies of AMD and VA loss that include the NEI-VFQ as an outcome measure.

Group Information: A complete list of members of the AREDS Research Group was published in Arch Ophthalmol. 2004;122:723-724.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Improved Vision-Related Function After Ranibizumab vs Photodynamic Therapy: A Randomized Clinical Trial
Bressler et al.
Arch Ophthalmol 2009;127:13-21.
ABSTRACT | FULL TEXT  

Improved Vision-Related Function After Ranibizumab Treatment of Neovascular Age-Related Macular Degeneration: Results of a Randomized Clinical Trial
Chang et al.
Arch Ophthalmol 2007;125:1460-1469.
ABSTRACT | FULL TEXT  

Burden of illness, visual impairment and health resource utilisation of patients with neovascular age-related macular degeneration: results from the UK cohort of a five-country cross-sectional study
Lotery et al.
Br. J. Ophthalmol. 2007;91:1303-1307.
ABSTRACT | FULL TEXT  

Burden and Health Care Resource Utilization in Neovascular Age-Related Macular Degeneration: Findings of a Multicountry Study
Soubrane et al.
Arch Ophthalmol 2007;125:1249-1254.
ABSTRACT | FULL TEXT